FDA Draft Guidance Clarifies OTC Time & Extent Applications
This article was originally published in The Rose Sheet
Executive Summary
Time & extent applications for OTC monograph eligibility should describe adverse event reporting systems in countries outside the U.S. where active ingredients have been marketed, according to an FDA draft guidance
You may also be interested in...
TEA Fee For Expedited Review, Dedicated Staff Increase Suggested
FDA should consider establishing a voluntary fee option for expedited reviews of OTC monograph time and extent applications, Ciba Specialty Chemicals recommends in April 13 comments to the agency
TEA Fee For Expedited Review, Dedicated Staff Increase Suggested
FDA should consider establishing a voluntary fee option for expedited reviews of OTC monograph time and extent applications, Ciba Specialty Chemicals recommends in April 13 comments to the agency
OTC “Time & Extent” Requirements Reduced For Extensively Marketed Drugs
Sponsors of OTC drugs with extensive foreign marketing experience need not provide detailed information from each country in requesting the drug or "condition" be considered for OTC monograph eligibility in the U.S., FDA says